Genmab
GMAB
142 hedge funds and large institutions have $640M invested in Genmab in 2020 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 53 increasing their positions, 45 reducing their positions, and 18 closing their positions.
61% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 18
18% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 45
13% more capital invested
Capital invested by funds: $564M → $640M (+$75.7M)
7.35% more ownership
Funds ownership: 36.42% → 43.77% (+7.4%)
7% more funds holding
Funds holding: 133 → 142 (+9)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
99% less call options, than puts
Call options by funds: $2K | Put options by funds: $256K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WRF
Waddell & Reed Financial
Overland Park,
Kansas
|
+$34.3M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
+$14.6M |
| 3 |
RG
Redmile Group
San Francisco,
California
|
+$13.6M |
| 4 |
BlackRock
New York
|
+$13.3M |
| 5 |
Jennison Associates
New York
|
+$13.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ZP
Zimmer Partners
New York
|
-$16.7M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$9.32M |
| 3 |
FAM
Fred Alger Management
New York
|
-$4.3M |
| 4 |
Artisan Partners
Milwaukee,
Wisconsin
|
-$3.67M |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$1.6M |
GMAB Hedge Fund Activity: Q1 2020 in Review
142 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Genmab (GMAB) for Q1 2020, worth a combined $640M — up 13% from $564M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new GMAB positions and 18 closed out — a net gain of 11 holders — while 53 added to existing stakes and 45 trimmed.
The largest buyer was Waddell & Reed Financial, opening a new position worth an estimated $34.3M. The largest seller was Zimmer Partners, exiting entirely with an estimated $16.7M sold.
- 142 institutional investors held Genmab (GMAB) as of Q1 2020, up from 133 in Q4 2019.
- Funds reported $640M of Genmab stock for Q1 2020, up 13% quarter-over-quarter.
- 29 funds opened new Genmab positions in Q1 2020 and 18 closed out, a net change of +11 holders.
- The largest Genmab buyer in Q1 2020 was Waddell & Reed Financial, an estimated $34.3M added.
- The largest Genmab seller in Q1 2020 was Zimmer Partners, an estimated $16.7M sold.
Based on aggregated 13F filings for Q1 2020.